{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:39Z","timestamp":1791348579904,"version":"4.3.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary aldosteronism (PA) is the most common and potentially curable endocrine cause of secondary hypertension, and carries a worse prognosis than essential hypertension. Despite the high prevalence of hypertension in patients with chronic kidney disease (CKD), the screening rates for primary aldosteronism in CKD are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we retrospectively reviewed medical records of 1627 adults who presented to the nephrology clinics of 2 tertiary hospitals in Melbourne, Australia, between 2014 and 2019. In addition to assessing the pattern of screening, we also evaluated patient-specific factors associated with the decision to test for primary aldosteronism. Patients were excluded from the final analysis if they did not have CKD, had an organ transplant, had end stage renal failure, or had insufficient data or follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 600 patients included in the analysis, 234 (39%) had an indication for screening for primary aldosteronism\u00a0based on recommendations made by the Endocrine Society. However, only 33 (14%) were tested. They were younger, had a higher mean systolic blood pressure, better renal function, and lower mean serum potassium than those who were indicated but not screened. Of the 33 screened patients, an elevated aldosterone-to-renin ratio was noted in 8 patients and a diagnosis of primary aldosteronism was made in 4 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The screening rate for primary aldosteronism is low in a CKD population, especially in patients who are older, have a lower eGFR and normal serum potassium. The consequences of undiagnosed primary aldosteronism in this select population may be substantial due to the cardiovascular and renal sequelae associated with untreated disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01267-3","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T05:02:54Z","timestamp":1645592574000},"page":"1667-1677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Screening for primary aldosteronism is underutilised in patients with chronic kidney disease"],"prefix":"10.1093","volume":"35","author":[{"given":"Karanjeet","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Schachna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Libianto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"issue":"8","key":"1267_CR1","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1097\/HJH.0000000000002087","volume":"37","author":"GA Head","year":"2019","unstructured":"Head GA, Shaw JE, Dunstan DW et al (2019) Hypertension, white-coat hypertension and masked hypertension in Australia: findings from the Australian Diabetes, Obesity, and Lifestyle Study 3. Am J Hypertens 37(8):1615\u20131623","journal-title":"Am J Hypertens"},{"issue":"3","key":"1267_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ndt\/gfv427","volume":"31","author":"L De Nicola","year":"2016","unstructured":"De Nicola L, Zoccali C (2016) Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant 31(3):331\u2013335","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1267_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR (2019) Hypertension in CKD: core curriculum 2019. Am J Kidney Dis 74(1):120\u2013131","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1267_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/BF03349761","volume":"18","author":"RD Gordon","year":"1995","unstructured":"Gordon RD (1995) Primary aldosteronism. J Endocrinol Invest 18(7):495\u2013511","journal-title":"J Endocrinol Invest"},{"issue":"25","key":"1267_CR5","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJM199812173392507","volume":"339","author":"A Ganguly","year":"1998","unstructured":"Ganguly A (1998) Primary aldosteronism. N Engl J Med 339(25):1828\u20131834","journal-title":"N Engl J Med"},{"issue":"1","key":"1267_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1210\/jc.2004-1149","volume":"90","author":"S-C Tiu","year":"2005","unstructured":"Tiu S-C, Choi C-H, Shek C-C et al (2005) The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 90(1):72\u201378","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1267_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0889-8529(02)00013-0","volume":"31","author":"VM Montori","year":"2002","unstructured":"Montori VM, Young Jr W (2002) Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin N Am. 31(3):619\u2013632 (xi)","journal-title":"Endocrinol Metab Clin N Am."},{"issue":"3","key":"1267_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","volume":"19","author":"G-P Rossi","year":"2008","unstructured":"Rossi G-P, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW (2008) Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 19(3):88\u201390","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"1267_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ncpneph0151","volume":"2","author":"C Mattsson","year":"2006","unstructured":"Mattsson C, Young WF (2006) Primary aldosteronism: diagnostic and treatment strategies. Nat Rev Nephrol 2(4):198\u2013208","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"1267_CR10","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, Monticone S, Bertello C et al (2013) Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 98(12):4826\u20134833","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1267_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke M, Fischer E, Gerum S et al (2012) Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension 60(3):618\u2013624","journal-title":"Hypertension"},{"issue":"1","key":"1267_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C et al (2018) Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6(1):41\u201350","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1267_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45(8):1243\u20131248","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1267_CR14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1681\/ASN.2004100878","volume":"16","author":"J Ribstein","year":"2005","unstructured":"Ribstein J, Cailar GD, Fesler P, Mimran A (2005) Relative glomerular hyperfiltration in primary aldosteronism. JASN 16(5):1320\u20131325","journal-title":"JASN"},{"issue":"22","key":"1267_CR15","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"LA Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R et al (2006) Long-term renal outcomes in patients with primary aldosteronism. JAMA 295(22):2638\u20132645","journal-title":"JAMA"},{"key":"1267_CR16","doi-asserted-by":"crossref","unstructured":"Ogata H, Yamazaki Y, Tezuka Y, et al (2021) Renal injuries in primary aldosteronism: quantitative histopathological analysis of 19 patients with primary adosteronism. Hypertension, p HYPERTENSIONAHA-121.","DOI":"10.1161\/HYPERTENSIONAHA.121.17436"},{"issue":"7","key":"1267_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/iju.12029","volume":"20","author":"T Utsumi","year":"2013","unstructured":"Utsumi T, Kawamura K, Imamoto T et al (2013) Preoperative masked renal damage in Japanese patients with primary aldosteronism: Identification of predictors for chronic kidney disease manifested after adrenalectomy. Int J Urol 20(7):685\u2013691","journal-title":"Int J Urol"},{"issue":"1","key":"1267_CR18","doi-asserted-by":"publisher","first-page":"32103","DOI":"10.1038\/srep32103","volume":"6","author":"V-C Wu","year":"2016","unstructured":"Wu V-C, Wang S-M, Chang C-H, Hu Y-H, Lin L-Y, Lin Y-H et al (2016) Long term outcome of Aldosteronism after target treatments. Sci Rep 6(1):32103","journal-title":"Sci Rep"},{"issue":"3","key":"1267_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","volume":"72","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A (2018) Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72(3):658\u2013666","journal-title":"Hypertension"},{"issue":"4","key":"1267_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","volume":"71","author":"GP Rossi","year":"2018","unstructured":"Rossi GP, Maiolino G, Flego A et al (2018) Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 71(4):585\u2013591","journal-title":"Hypertension"},{"issue":"6","key":"1267_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCOUTCOMES.115.002002","volume":"8","author":"CC Lubitz","year":"2015","unstructured":"Lubitz CC, Economopoulos KP, Sy S et al (2015) Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients. Circ Cardiovasc Qual Outcomes 8(6):621\u2013630","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"1267_CR22","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW (1955) Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45(1):3\u201317","journal-title":"J Lab Clin Med"},{"issue":"7","key":"1267_CR23","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC K\u00e4yser","year":"2016","unstructured":"K\u00e4yser SC, Dekkers T, Groenewoud HJ et al (2016) Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 101(7):2826\u20132835","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1267_CR24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"RM Carey","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101(5):1889\u20131916","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1267_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","volume":"75","author":"G Jaffe","year":"2020","unstructured":"Jaffe G, Gray Z, Krishnan G et al (2020) Screening rates for primary aldosteronism in resistant hypertension. Hypertension 75(3):650\u2013659","journal-title":"Hypertension"},{"issue":"6","key":"1267_CR26","first-page":"541","volume":"156","author":"Y Liu","year":"2021","unstructured":"Liu Y, King J, Kline GA et al (2021) Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism. JAMA 156(6):541\u2013549","journal-title":"JAMA"},{"issue":"7","key":"1267_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1097\/HJH.0000000000002046","volume":"37","author":"J Wu","year":"2019","unstructured":"Wu J, Tian W, Zhang L, Zhang J, Zhou B (2019) Assessing the quality of guidelines for primary aldosteronism: which guidelines are worth applying in diverse settings? J Hypertens 37(7):1500","journal-title":"J Hypertens"},{"issue":"3","key":"1267_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/1573402113666161122114854","volume":"12","author":"Q-F Huang","year":"2016","unstructured":"Huang Q-F, Hoshide S, Cheng H-M et al (2016) Management of hypertension in patients with chronic kidney disease in Asia. Curr Hypertens Rev 12(3):181\u2013185","journal-title":"Curr Hypertens Rev"},{"key":"1267_CR29","unstructured":"National Heart Foundation of Australia, National Blood Pressure and Vascular Disease Advisory Committee (2016) Guideline for the diagnosis and management of hypertension in adults"},{"issue":"3","key":"1267_CR30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung AK, Chang TI, Cushman WC et al (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3):S1-87","journal-title":"Kidney Int"},{"issue":"1","key":"1267_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.surg.2019.05.087","volume":"167","author":"M Sivarajah","year":"2020","unstructured":"Sivarajah M, Beninato T, Fahey TJ (2020) Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system. Surgery 167(1):211\u2013215","journal-title":"Surgery"},{"issue":"03","key":"1267_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1055\/s-0031-1295460","volume":"44","author":"M Stowasser","year":"2012","unstructured":"Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD (2012) Factors affecting the aldosterone\/renin ratio. Horm Metab 44(03):170\u2013176","journal-title":"Horm Metab"},{"issue":"6","key":"1267_CR33","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1210\/jc.2010-2918","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M (2011) Effect of contraceptives on aldosterone\/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 96(6):1797\u20131804","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1267_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.mpmed.2011.04.007","volume":"39","author":"PD Evans","year":"2011","unstructured":"Evans PD, Taal MW (2011) Epidemiology and causes of chronic kidney disease. Medicine 39(7):402\u2013406","journal-title":"Medicine"},{"issue":"9455","key":"1267_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. The Lancet 365(9455):217\u2013223","journal-title":"The Lancet"},{"issue":"3","key":"1267_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","volume":"174","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V (2021) Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans. Ann Intern Med 174(3):289\u2013297","journal-title":"Ann Intern Med"},{"issue":"1","key":"1267_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/02813432.2015.1132885","volume":"34","author":"VAV Gelder","year":"2016","unstructured":"Gelder VAV, Haan NDS-D, Grauw WJCD et al (2016) Quality of chronic kidney disease management in primary care: a retrospective study. Scand J Prim Health Care 34(1):73\u201380","journal-title":"Scand J Prim Health Care"},{"issue":"11","key":"1267_CR38","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48(11):2293\u20132300","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1267_CR39","doi-asserted-by":"publisher","first-page":"712","DOI":"10.31128\/AJGP-05-18-4587","volume":"47","author":"YY Lim","year":"2018","unstructured":"Lim YY, Shen J, Fuller PJ, Yang J (2018) Current pattern of primary aldosteronism diagnosis: delayed and complicated. Aust J Gen Pract 47(10):712\u2013718","journal-title":"Aust J Gen Pract"},{"issue":"6","key":"1267_CR40","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","volume":"40","author":"P Mulatero","year":"2002","unstructured":"Mulatero P, Rabbia F, Milan A et al (2002) Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism. Hypertension 40(6):897\u2013902","journal-title":"Hypertension"},{"issue":"7","key":"1267_CR41","first-page":"e13353","volume":"73","author":"PM O'Shea","year":"2019","unstructured":"O\u2019Shea PM, Griffin TP, Denieffe S, Fitzgibbon MC (2019) The aldosterone to renin ratio in the diagnosis of primary aldosteronism: promises and challenges. Int J Clin 73(7):e13353","journal-title":"Int J Clin"},{"key":"1267_CR42","doi-asserted-by":"crossref","unstructured":"J\u0119drusik P, Symonides B, Lewandowski J, Gaciong Z (2021) The effect of antihypertensive medications on testing for primary aldosteronism. Front Pharmacol 12","DOI":"10.3389\/fphar.2021.684111"},{"issue":"2","key":"1267_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.ackd.2014.09.004","volume":"22","author":"B Horowitz","year":"2015","unstructured":"Horowitz B, Miskulin D, Zager P (2015) Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis 22(2):88\u201395","journal-title":"Adv Chronic Kidney Dis"},{"key":"1267_CR44","doi-asserted-by":"crossref","unstructured":"Ergin AB, Hamrahian AH, Kennedy AL, Gupta MK (2015) Intravenous Saline suppression test. In: The Cleveland Clinic manual of dynamic endocrine testing. Springer, Cham, pp 59\u201362","DOI":"10.1007\/978-3-319-13048-4_15"},{"issue":"2","key":"1267_CR45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1470320310391331","volume":"12","author":"C-C Kuo","year":"2011","unstructured":"Kuo C-C, Wu V-C, Tsai C-W, Wu K-D (2011) Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis. J Renin Angiotensin Aldosterone Syst 12(2):113\u2013122","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"23","key":"1267_CR46","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"3","key":"1267_CR47","first-page":"294","volume":"114","author":"H Koshida","year":"1989","unstructured":"Koshida H, Miyamori I, Miyazaki R, Tofuku Y, Takeda R (1989) Falsely elevated plasma aldosterone concentration by direct radioimmunoassay in chronic renal failure. J Lab Clin Med 114(3):294\u2013300","journal-title":"J Lab Clin Med"},{"issue":"6","key":"1267_CR48","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1373\/clinchem.2016.255737","volume":"62","author":"L Lam","year":"2016","unstructured":"Lam L, Chiu WW, Davidson JS (2016) Overestimation of aldosterone by immunoassay in renal impairment. Clin Chem 62(6):890\u2013891","journal-title":"Clin Chem"},{"issue":"1","key":"1267_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hen\u00e9","year":"1982","unstructured":"Hen\u00e9 RJ, Boer P, Koomans HA, Mees EJ (1982) Plasma aldosterone concentrations in chronic renal disease. Kidney Int 21(1):98\u2013101","journal-title":"Kidney Int"},{"issue":"14","key":"1267_CR50","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM197109302851401","volume":"285","author":"P Weidmann","year":"1971","unstructured":"Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG (1971) Plasma renin activity and blood pressure in terminal renal failure. NEJM 285(14):757\u2013762","journal-title":"NEJM"},{"issue":"2","key":"1267_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","volume":"67","author":"G Thomas","year":"2016","unstructured":"Thomas G, Xie D, Chen H-Y et al (2016) Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease. Hypertension 67(2):387\u2013396","journal-title":"Hypertension"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01267-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01267-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01267-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:59Z","timestamp":1777564499000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/6\/1667\/8325782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01267-3","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"5 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The results presented in this paper have not been published elsewhere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. This was done in line with the principles of the 1964 Helsinki Declaration. Approval was granted by the Human Research Ethics Committees of Monash Health and Alfred Health (Australia). The confidentiality of the data was maintained during the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}